Why the study?
The selection of escalation of care strategies for treating intermediate-risk pulmonary embolism remains a matter of debate.
Does catheter-directed thrombolysis reduce discharge systolic pulmonary artery pressure compared to anticoagulation alone in patients with intermediate-high-risk pulmonary embolism?
Does catheter-directed thrombolysis reduce discharge systolic pulmonary artery pressure compared to anticoagulation alone in patients with intermediate-high-risk pulmonary embolism?
In a retrospective cohort of intermediate-high-risk PE patients, catheter-directed thrombolysis was associated with lower discharge sPAP compared to anticoagulation alone, though it was selected for patients with lower baseline bleeding risk.
Answers are grounded in this paper and cite their sources.
Lower discharge sPAP with CDT in selected patients; leaves open whether CDT improves outcomes versus anticoagulation in intermediate-high-risk PE.
BACKGROUND AND OBJECTIVES: The selection of escalation of care strategies for the treatment of intermediate-risk pulmonary embolism (PE) is a matter of debate. Here, we aimed to assess the features of our population treated either with anticoagulation (AC) alone or catheter-directed thrombolysis (CDT). We also sought to identify a relationship between high residual systolic pulmonary artery pressure (sPAP) and demographic and clinical variables.PATIENTS AND METHODS: The retrospective data of 30 intermediate-high-risk PE patients were analyzed. CDT was used in 14 (46.7%) cases. Enoxaparin (b. i. d) injections were administered in the AC group. In the CDT group, patients received 5 mg bolus dose of alteplase followed by 1 mg/h infusion for 24 h. Estimated sPAP at presentation and discharge was recorded. A value equal to or greater than 40 mmHg in the latter was accepted as a significant rise.RESULTS: The patients in the CDT group had a lower HAS-BLED score (2 [0–3] vs. 1 [0–3], P = 0.03). Although initial sPAP values were comparable among treatment arms, sPAP at discharge was significantly lower in the CDT group (mmHg, 42 ± 11.2 vs. 33.6 ± 9.7, P = 0.04). The reduction in sPAP at discharge was also significantly higher in this group. The degree of reduction in sPAP was considerably correlated with baseline sPAP (r: 63.2, P < 0.001). Finally, the baseline sPAP measurement and HAS-BLED score of the patients with high residual sPAP were significantly higher (56.6 ± 13.1 vs. 67.3 ± 11.3, P = 0.02, and 1 [0–3] vs. 2 [0–3], P = 0.02, respectively).CONCLUSION: CDT was preferred over AC when lower bleeding risk was anticipated for intermediate-high-risk PE patients in our sample population. Eventually, CDT provided lower discharge sPAP levels and a greater reduction in sPAP. However, the factors associated with high sPAP at discharge were only high baseline sPAP measurement and HAS-BLED score.
No takes yet. Share an insight, caveat, or question.
Omaygenc et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: